Hospital at Home Outcomes and Costs from Propensity-Matched Cohort

2,905 episodes of Hospital at Home care were analyzed against a matched inpatient control cohort to evaluate clinical and economic outcomes. The study, authored by Michael Shaw and published in 2026, found significant reductions in length of stay, 30-day readmissions, and 90-day mortality. It covers patient admissions from December 2021 to May 2024 for conditions including heart function, airway disease, and acute respiratory infection.

Use Cases

• Compare length_of_stay and total_bed_day_costs between Hospital at Home and inpatient cohorts to model healthcare savings.
• Predict 30_day_readmission_rates using patient pathways and treatment setting as features.
• Analyze 90_day_mortality odds ratios to assess the safety of home-based care for specific conditions.
• Model patient_experience_and_acceptability_metrics against clinical outcomes to optimize service design.

Strengths

• Analysis of 2,972 HAH episodes with a 1:1 propensity-matched control cohort of 1,488 inpatient episodes.
• Results include statistically significant effect sizes (e.g., 3.13-day bed-day savings, p < 1e-29) and cost savings of £3.79 million.
• Covers a 33-month time range from December 2021 to May 2024, providing recent real-world evidence.

Limitations

• Dataset is small in file size (89.6 KB), suggesting it contains summary results rather than raw patient-level data.
• Geographic scope is limited to a single service in England, which may limit generalizability.
• The DOCX format indicates the data is likely embedded in a research paper table, requiring extraction for computational analysis.

Provenance

Source

Michael Shaw via figshare.

Collection Method

Retrospective cohort study using propensity score matching and regression adjustment.

Time Range

December 2021 to May 2024.

Freshness

Last updated in April 2026, based on data through May 2024.

Geography

England (specific HAH service location not specified).